Actemra for children and young adults with craniopharyngioma
Treatments studied
Part of Cancer clinical trials.
This trial studies Actemra (tocilizumab) to slow or shrink adamantinomatous craniopharyngioma, a brain tumor that can recur after treatment. You may be eligible if you’re within the age range and have measurable tumor on scan, with specific rules about prior therapy and recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 12 months old and 39 years old when you join
- Have adamantinomatous craniopharyngioma confirmed by pathology, or a cyst fluid sample when a solid tumor can’t be taken safely
- Have measurable tumor disease (something the team can track on scans)
- Have stable neurologic symptoms for at least about 1 week before enrolling, if you have symptoms
- Be well enough overall (performance score threshold) and have had recovery from prior treatments
- Have adequate blood counts, kidney, and liver function based on lab tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests MEKTOVI® to treat pediatric adamantinomatous craniopharyngioma (a type of brain tumor). It may help shrink or control the tumor after it has come back or grown again.
This trial tests a treatment that targets tumor blood-vessel growth to slow or shrink relapsed/progressive brain tumors in children. It may help if standard options are no longer working.
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This trial studies tovorafenib to treat craniopharyngioma in children and young adults. It aims to shrink the tumor or slow its growth, and to learn which patients benefit most and what side effects to expect.
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
Hear when a new Adamantinomatous Craniopharyngioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.